VANCOUVER, BC / ACCESS Newswire / October 2, 2025 /BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a development-stage biopharmaceutical company specializing in ...

In this interview, Dr. Freya Leech, a researcher at NanoFCM, discusses the current challenges and future prospects in ...

While AMT-130 could result in meaningful revenue for ClearPoint, the Huntington's opportunity is relatively modest compared ...

Recurring fever, fatigue, pale skin, bruising, or bone pain in children may signal leukaemia. Early diagnosis is vital, as modern treatments now offer over 80% cure rates and improved survival ...

In a preclinical study, UC Davis Comprehensive Cancer Center scientists developed a highly targeted gene therapy that could revolutionize treatment for cancers linked to a common herpesvirus, with ...

Approval of a second generic is unlikely to affect access to the pill, which is typically taken with another drug, ...

Rnai Therapeutics Market To Hit $8.8B By 2033, Driven By Rare & Cardiovascular Diseases & Sirna And Delivery Innovations. therapeutics represent one of the most exciting frontiers in precision ...

The clearance gives Distalmotion, which sees opportunity in ambulatory settings, a third robotic procedure category in the ...

Iopofosine I 131 is a potential first-in-class, novel cancer targeting agent utilizing a phospholipid ether as a ...

METiS TechBio, a pioneer in AI-powered nano-delivery innovation, announced the official launch of NanoForge, the world's first end-to-end AI-driven nano-delivery platform. Dr. Chris Lai, Co-Founder ...

In a preclinical study, UC Davis Comprehensive Cancer Center scientists have developed a highly targeted gene therapy that ...

Jessica Katawick's whole life changed on a September morning in 2020. "As soon as my feet hit the floor something said I should just do a breast exam today. I just knew it was breast cancer," said ...